Home » Topics » BioWorld Science

BioWorld Science
RSS

New chemical entities designed by DINGOS machine learning model

Aug. 20, 2019

LDD-1819 has cell reprograming and dual kinase inhibitory activity

Aug. 20, 2019

Bristol-Myers Squibb discovers receptor-interacting serine/threonine-protein kinase 1 inhibitors

Aug. 20, 2019

RNA-binding protein 39 degradation inducers patented by the Dana-Farber Cancer Institute

Aug. 20, 2019

First-in-human results for the chlamydia vaccine candidate CTH-522

Aug. 20, 2019

IP-1867B ablates EGFR inhibitor resistance in adult high-grade gliomas

Aug. 20, 2019

Fulcrum Therapeutics initiates phase IIb ReDUX4 study of losmapimod in FSHD

Aug. 19, 2019

Bird Rock Bio initiates phase II study of nimacimab in patients with diabetic gastroparesis

Aug. 19, 2019

Patient recruitment initiated in phase II study of TQ-B3101 in ROS1-positive NSCLC

Aug. 19, 2019

Recruitment ongoing in Janssen's first-in-human study of JNJ-74699157

Aug. 19, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Latus Bio series A financing supports early-stage programs
BioWorld Science
Latus Bio Inc. has closed a $97 million series A financing to support its broad therapeutics pipeline based on novel AAV capsid variants. Proceeds from the...